# OnCo record nct07217184 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07217184/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07217184", "NCT07217184" ;
  schema:name "Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM"@en ;
  schema:description "A phase 1/2 trial of Belantamab mafodotin, Isatuximab in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07217184/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07217184> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2021-07-29" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/belantamab-mafodotin/>, <https://onco.cc/drugs/isatuximab/> ;
  onco:companies <https://onco.cc/companies/gsk/> .